{"id":"NCT00326209","sponsor":"Bausch Health Americas, Inc.","briefTitle":"Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission","officialTitle":"A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine Pellet Formulation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12-22","primaryCompletion":"2008-05-05","completion":"2008-05-05","firstPosted":"2006-05-16","resultsPosted":"2019-11-01","lastUpdate":"2019-11-01"},"enrollment":393,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Encapsulated Mesalamine Granules (eMG)","otherNames":["Mesalamine pellets"]}],"arms":[{"label":"Encapsulated Mesalamine Granules (eMG)","type":"EXPERIMENTAL"}],"summary":"To evaluate the long-term safety and tolerability of encapsulated mesalamine Granules (eMG) (formerly referred to as Mesalamine Pellets \\[MP\\]) in participants with ulcerative colitis currently in remission.","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"Baseline (Day 1) up to follow-up (24.5 months)","effectByArm":[{"arm":"Encapsulated Mesalamine Granules (eMG)","deltaMin":280,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":61,"countries":["United States"]},"refs":{"pmids":["26563167"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":388},"commonTop":["Nasopharyngitis","Headache","Diarrhea","Abdominal Pain","Sinusitis"]}}